Jean-Luc Brun1, José Rajaonarison2, Alizée Froeliger3, Anne-Coline Monseau-Thiburce4, Rado Randriamboavonjy5, Andrej Vogler6. 1. Department of Obstetrics and Gynecology, University Hospital of Bordeaux, Bordeaux, France. Electronic address: jean-luc.brun@chu-bordeaux.fr. 2. Department of Obstetrics and Gynecology, University Hospital of Bordeaux, Bordeaux, France. Electronic address: drjoserajaonarison@gmail.com. 3. Department of Obstetrics and Gynecology, University Hospital of Bordeaux, Bordeaux, France. Electronic address: alizee.froeliger@hotmail.fr. 4. Department of Imaging, University Hospital of Bordeaux, Bordeaux, France. Electronic address: anne-coline.thiburce@chu-bordeaux.fr. 5. Laboratoire d'appui à la recherche et technologie de l'information et de la communication LARTIC laboratories, University of Antananarivo, Antananarivo, Madagascar. Electronic address: radolalaorandria@yahoo.fr. 6. Department of Obstetrics and Gynecology, University Medical Center Ljubljana, Ljubljana, Slovenia. Electronic address: andrej.vogler@guest.arnes.si.
Abstract
OBJECTIVES: To determine the proportion and the characteristics of patients who did or did not respond after 3 months of ulipristal acetate (UPA) therapy. STUDY DESIGN: In this retrospective cohort study conducted in the University Hospital of Bordeaux (France) and University Medical Center Ljubljana (Slovenia), symptomatic non-menopausal patients with fibroids that qualified for surgery were pretreated by 3 months of oral UPA 5 mg/day. Clinical success was defined by normalization of the bleeding score, and/or regression of pelvic pain, and/or abdominal distension. Imaging success was defined by reduction in fibroid volume ≥ 25%. RESULTS: The clinical and imaging success rates were 54/66 (82%) and 39/66 (59%) respectively. The absence of previous pregnancy (p = 0.004) and the size of the dominant fibroid ≥ 80 mm (p = 0.004) were independent factors associated with clinical failure. Age <35 years (p = 0.02) was the only independent factor associated with imaging failure. CONCLUSION: Young women developing fibroids and/or women with large fibroids may be resistant to ulipristal acetate therapy.
OBJECTIVES: To determine the proportion and the characteristics of patients who did or did not respond after 3 months of ulipristal acetate (UPA) therapy. STUDY DESIGN: In this retrospective cohort study conducted in the University Hospital of Bordeaux (France) and University Medical Center Ljubljana (Slovenia), symptomatic non-menopausal patients with fibroids that qualified for surgery were pretreated by 3 months of oral UPA 5 mg/day. Clinical success was defined by normalization of the bleeding score, and/or regression of pelvic pain, and/or abdominal distension. Imaging success was defined by reduction in fibroid volume ≥ 25%. RESULTS: The clinical and imaging success rates were 54/66 (82%) and 39/66 (59%) respectively. The absence of previous pregnancy (p = 0.004) and the size of the dominant fibroid ≥ 80 mm (p = 0.004) were independent factors associated with clinical failure. Age <35 years (p = 0.02) was the only independent factor associated with imaging failure. CONCLUSION: Young women developing fibroids and/or women with large fibroids may be resistant to ulipristal acetate therapy.